Cargando…

Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer

PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Noah C., Chun, Tristen T., Niemierko, Andrzej, Ancukiewicz, Marek, Fidias, Panos M., Kradin, Richard L., Mathisen, Douglas J., Lynch, Thomas J., Fischman, Alan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644202/
https://www.ncbi.nlm.nih.gov/pubmed/23400506
http://dx.doi.org/10.1007/s00259-013-2348-4
_version_ 1782268430877982720
author Choi, Noah C.
Chun, Tristen T.
Niemierko, Andrzej
Ancukiewicz, Marek
Fidias, Panos M.
Kradin, Richard L.
Mathisen, Douglas J.
Lynch, Thomas J.
Fischman, Alan J.
author_facet Choi, Noah C.
Chun, Tristen T.
Niemierko, Andrzej
Ancukiewicz, Marek
Fidias, Panos M.
Kradin, Richard L.
Mathisen, Douglas J.
Lynch, Thomas J.
Fischman, Alan J.
author_sort Choi, Noah C.
collection PubMed
description PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression. RESULTS: We accrued 106 patients, of whom 61 completed the serial (18)F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g for tumors with local control and 0.12, 0.16 and 0.19 μmol/min/g for tumors with local failure, and the maximum standard uptake values (SUVmax) were 1.16, 1.33 and 1.45 for tumors with local control and 2.74, 2.74 and 4.07 for tumors with local failure (p < 0.0001). MRglc-MMR was realized at S2 (MRglc-S2) and the values corresponding to TCP 95 %, 90 % and 50 % were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and 0.70, 0.91 and 1.95 using SUVmax, respectively. Probability cut-off values were generated for a given level of MRglc-S2 based on its predicted TCP, sensitivity and specificity, and MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were determined as the optimum cut-off values for predicted TCP 80 %, sensitivity 100 % and specificity 63 %. CONCLUSION: The cut-off values (MRglc ≤0.071 μmol/min/g using the SKM and SUVmax ≤1.45) need to be tested for their utility in identifying patients with a high risk of residual cancer after standard dose radiotherapy or chemoradiotherapy and in guiding a timely supplementary dose of radiation or other means of salvage therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-013-2348-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3644202
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-36442022013-05-06 Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer Choi, Noah C. Chun, Tristen T. Niemierko, Andrzej Ancukiewicz, Marek Fidias, Panos M. Kradin, Richard L. Mathisen, Douglas J. Lynch, Thomas J. Fischman, Alan J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression. RESULTS: We accrued 106 patients, of whom 61 completed the serial (18)F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g for tumors with local control and 0.12, 0.16 and 0.19 μmol/min/g for tumors with local failure, and the maximum standard uptake values (SUVmax) were 1.16, 1.33 and 1.45 for tumors with local control and 2.74, 2.74 and 4.07 for tumors with local failure (p < 0.0001). MRglc-MMR was realized at S2 (MRglc-S2) and the values corresponding to TCP 95 %, 90 % and 50 % were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and 0.70, 0.91 and 1.95 using SUVmax, respectively. Probability cut-off values were generated for a given level of MRglc-S2 based on its predicted TCP, sensitivity and specificity, and MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were determined as the optimum cut-off values for predicted TCP 80 %, sensitivity 100 % and specificity 63 %. CONCLUSION: The cut-off values (MRglc ≤0.071 μmol/min/g using the SKM and SUVmax ≤1.45) need to be tested for their utility in identifying patients with a high risk of residual cancer after standard dose radiotherapy or chemoradiotherapy and in guiding a timely supplementary dose of radiation or other means of salvage therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-013-2348-4) contains supplementary material, which is available to authorized users. Springer-Verlag 2013-02-12 2013 /pmc/articles/PMC3644202/ /pubmed/23400506 http://dx.doi.org/10.1007/s00259-013-2348-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Choi, Noah C.
Chun, Tristen T.
Niemierko, Andrzej
Ancukiewicz, Marek
Fidias, Panos M.
Kradin, Richard L.
Mathisen, Douglas J.
Lynch, Thomas J.
Fischman, Alan J.
Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
title Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
title_full Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
title_fullStr Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
title_full_unstemmed Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
title_short Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
title_sort potential of (18)f-fdg pet toward personalized radiotherapy or chemoradiotherapy in lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644202/
https://www.ncbi.nlm.nih.gov/pubmed/23400506
http://dx.doi.org/10.1007/s00259-013-2348-4
work_keys_str_mv AT choinoahc potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT chuntristent potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT niemierkoandrzej potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT ancukiewiczmarek potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT fidiaspanosm potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT kradinrichardl potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT mathisendouglasj potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT lynchthomasj potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer
AT fischmanalanj potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer